RxDoctor Payments Data

Aparna Bhagavat, MD

Cardiovascular Disease · San Mateo, CANPI 1144254806

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 49 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$140
  • Heartflow, Inc.$100
  • Novartis$93
  • Boston Scientific$91
  • E.r. Squibb & Sons, L.L.C.$87
  • Johnson & Johnson$77
  • plus $437 from 11 others

What the payments were for

  • Food & beverage$1,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,026 in reported general payments places this provider in the 35th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$134,911
Medicare patients
686
Services billed
1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban361$463,857
JardianceEmpagliflozin92$107,528
XareltoRivaroxaban51$64,360
EntrestoSacubitril/Valsartan52$59,995
Repatha SureclickEvolocumab42$35,197
MultaqDronedarone Hcl11$12,865
FarxigaDapagliflozin Propanediol15$12,049
Metoprolol Succinate738$10,768
Rosuvastatin Calcium436$5,443
Losartan Potassium385$3,826
Lisinopril398$3,620
Carvedilol368$2,514
Clonidine13$2,329
Isosorbide Dinitrate39$2,075
Potassium Chloride115$2,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$463,857361 claims
Boehringer IngelheimJardiance$25$107,52892 claims
Johnson & JohnsonXarelto$77$64,36051 claims
NovartisEntresto$93$59,99552 claims
Sanofi-aventis U.S. LLCMultaq$24$12,86511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Mateo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →